---
title: 'Erdafitinib in patients with advanced solid tumours with FGFR alterations
  (RAGNAR): an international, single-arm, phase 2 study'
date: '2023-08-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37541273/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230805180723&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'BACKGROUND: FGFR alterations are reported across various malignancies
  and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral,
  selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced
  urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib
  in previously treated patients with FGFR-altered advanced solid ...'
disable_comments: true
---
BACKGROUND: FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid ...